Oxygen plays a significant role in wound healing, and maintaining elevated tissue oxygenation levels are an important factor in the dermal healing response. Specifically, non-healing diabetic chronic wounds (defined as lasting > 6 weeks) often show devastatingly low oxygen concentrations, as low as 5 mmHg oxygen partial pressure. In the USA, there are more than 29.1 million diabetics, with 1.7 million new cases every year. About 3-4 million new diabetic ulcers are diagnosed every year, and these numbers are increasing as our population ages. It is estimated that up to 25% of all diabetics will develop a foot ulcer, and a fifth of these cases will result in a chronic non-healing wound that requires amputation. Oxygen treatment has been demonstrated to promote chronic wound healing by enhancing metabolism, extracellular matrix synthesis, and neovascularization, all while limiting antimicrobial activity. Despite the benefits of supplemental oxygen, current oxygen delivery therapies are intermittent, inconvenient for the patient, and require access to expensive and specialized equipment. Hence, there is a significant need for a simple, low-cost wound dressing able to support regenerative levels of oxygen and to supplement or possibly supplant current therapies (hyperbaric oxygen, topical oxygen via tent/bag). This proposal provides a unique polymerized chitosan hydrogel sheet dressing that has the potential to provide uniform and tunable oxygenation across an ulcerous chronic wound. A biocompatible photocrosslinkable chitosan hydrogel covalently modified with perfluorocarbons (PFCs) has been invented. The wound dressing made from the hydrogel will be marketed under the name OXAID(tm) through the company O2 RegenTech LLC. OXAID uniquely allows for the creation of sheet hydrogels that covalently incorporate PFCs for sustained oxygenation for up to five days at significant oxygen partial pressures. Thus, OXAID potentially marries the benefits of oxygen treatment (above) with hydrogel dressings (increased angiogenesis, enhanced autolytic debridement, increased re-epithelialization). The primary goal of this project is to obtain proof that OXAID is safe and can deliver oxygen to effectively heal chronic wounds. The primary hypothesis is that the oxygen-loaded fluorinated hydrogel platform will provide both enhanced dermal healing responses significantly faster and more completely than both unoxygenated controls and a commercial sheet hydrogel dressing. To test this overall hypothesis, the Specific Aims are: 1. Scale up OXAID synthesis and characterize chemical and material properties; and 2. Conduct a pre-clinical in vivo feasibility study to evaluate the safety and efficacy of OXAID for diabetic chroni wound healing.

Public Health Relevance

Each year, there are close to 4 million incidences of chronic diabetic foot ulcers, which generate more than $1.5 billion in healthcare-related costs and $20 billion in both direct and indirect costs. The medical field needs inexpensive, effective treatments that can deliver faster and more powerful results. Our product OXAID(tm) is an oxygenated hydrogel sheet dressing that combines the powerful healing benefits of high-cost hyperbaric oxygen treatments with the low-cost application of common synthetic dressings to effectively eliminate chronic diabetic foot ulcers.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
1R41DK105704-01A1
Application #
9046090
Study Section
Special Emphasis Panel (ZRG1-MOSS-U (12)B)
Program Officer
Arreaza-Rubin, Guillermo
Project Start
2016-09-06
Project End
2017-08-31
Budget Start
2016-09-06
Budget End
2017-08-31
Support Year
1
Fiscal Year
2016
Total Cost
$224,977
Indirect Cost
Name
O2 Regentech, LLC
Department
Type
DUNS #
079300192
City
Akron
State
OH
Country
United States
Zip Code
44311